GSK, Pfizer RSV vaccine sales fall in US
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
There aren’t a lot of easy changes the drugmaker can make to right itself quickly. Boosting sales fast enough to lift shares will be hard, and high debts rule out a game-changing acquisition. Get the ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary.
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion ...
Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback